Henry Ford Health System and Syapse Partner to Launch Cancer Precision Medicine Program
In response to the White House Cancer Moonshot’s call for action, Henry Ford and Syapse will bring precision medicine to cancer patients in the greater Midwest
WASHINGTON, DC --- Henry Ford Health System, one of the nation's leading comprehensive and integrated health systems, and Syapse, the leading precision medicine software company, are announcing today the launch of an oncology precision medicine program to revolutionize cancer care in the greater Midwest. With the goal of increasing access to the best care for all patients, the Henry Ford-Syapse partnership will bring world class, targeted cancer treatments to this national destination referral center in Michigan and will continue to offer a bright beacon of hope to underserved populations in Detroit.
Responding to Vice President Joe Biden’s Cancer Moonshot Initiative, Henry Ford Health System commits to sharing cancer outcomes data with other health systems through the Syapse software platform, enabling more rapid learning from real-world experiences to improve patient care around the globe, today. Syapse and Henry Ford Health System will commit to making this data sharing a reality within 12 months.
Henry Ford Health System and Syapse are discussing this commitment to cancer precision medicine and data sharing during the White House Cancer Moonshot Summit today in Washington, D.C. Henry Ford Health System is being represented at the Summit by Steven N. Kalkanis, M.D., physician leader for cancer services at Henry Ford Health System. Syapse is being represented by Jonathan Hirsch, Founder & President.
“Partnering with Syapse brings the Cancer Moonshot’s vision of improved care to the Midwest in a way that delivers treatment that is built around an individual – encompassing Henry Ford’s new customer promise “All For You.” We have seen the power of targeted gene therapy in select patients. This initiative is a huge step forward in cancer care, allowing us to bring highly advanced options to all our patients, at all cancer stages, where in many cases hope was not present. ” says Dr. Kalkanis.
Henry Ford Health System has one of the largest cancer programs in Michigan, providing care at four hospitals and four outpatient treatment facilities. Approximately 5,500 new cancer patients are treated annually at Henry Ford, with plans in place for future clinical growth and expanded care.
Those plans include a new $110 million destination cancer center in Detroit that is set to open in 2018. The five-story, 144,000 square-foot facility will house ambulatory cancer treatment and enhanced support services under one roof to support patients’ emotional and physical needs through diagnosis and treatment to survival.
Over the coming months, Henry Ford Health System will launch the Syapse Precision Medicine Platform software solution across its key cancer care facilities, including the flagship Henry Ford Hospital in Detroit. The Syapse software platform is a category-defining solution for the clinical implementation of precision medicine, enabling integration of clinical and molecular data, decision support, care coordination, outcomes tracking, and quality improvement. Henry Ford will additionally use Syapse software to support their Molecular Tumor Board consult service, and match patients to clinical trials.
“Henry Ford has been known nationally for cancer research and care for decades through our Henry Ford Cancer Institute. The Precision Medicine Program and partnership with Syapse, coupled with the creation of our new Detroit cancer center, solidifies our unwavering commitment to our patients in Detroit and beyond to continuously advance cancer clinical care, research and innovation,” says John Popovich, Jr., M.D., President & CEO, Henry Ford Hospital. The Detroit region includes a high percentage of at-risk community members, with household incomes that are less than half the Michigan average.
“Through our new partnership with Henry Ford Health System, we will bring the promise of precision medicine to cancer patients in Detroit and the greater Midwest,” said Jonathan Hirsch, Syapse founder and president. “We believe that precision medicine will be a core enabling technology for health systems to transform to value-based care, and we’re excited to partner with Henry Ford Health System on this journey.”
About Henry Ford Health System
Henry Ford Health System is a six-hospital system headquartered in Detroit. It is one of the nation’s leading comprehensive, integrated health systems, recognized for clinical excellence and innovation. Henry Ford Health System provides both health insurance and health care delivery, including acute, specialty, primary and preventive care services backed by excellence in research and education. The system is a 2011 Malcolm Baldrige National Quality Award recipient. Visit www.henryford.com to learn more.
Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. Syapse Precision Medicine Platform is a comprehensive software suite used by leading health systems to support the clinical implementation of precision medicine in oncology and other service lines. This category-defining platform enables clinical and genomic data integration, decision support, care coordination, and quality improvement at point of care. Headquartered in Palo Alto, California, with offices in Philadelphia, Pennsylvania, Syapse is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), and Social Capital. For more information, visit syapse.com.
Henry Ford Health System: